501
Participants
Start Date
June 30, 2012
Primary Completion Date
November 30, 2013
Study Completion Date
November 30, 2013
GSK1838262 600 mg
Drug: GSK1838262 600 mg/day Comparison of 3 doses
GSK1838262 450 mg
Drug: GSK1838262 450 mg/day Comparison of 3 doses
GSK1838262 300 mg
Drug: GSK1838262 300 mg/day Comparison of 3 doses
GSK1838262 Placebo match
Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
GSK Investigational Site, Duncansville
GSK Investigational Site, Lafayette Hill
GSK Investigational Site, Chevy Chase
GSK Investigational Site, Charlottesville
GSK Investigational Site, Winston-Salem
GSK Investigational Site, Raleigh
GSK Investigational Site, Hickory
GSK Investigational Site, Columbia
GSK Investigational Site, Mt. Pleasant
GSK Investigational Site, Greer
GSK Investigational Site, Woodstock
GSK Investigational Site, Atlanta
GSK Investigational Site, DeLand
GSK Investigational Site, Tampa
GSK Investigational Site, Jackson
GSK Investigational Site, Louisville
GSK Investigational Site, Crestview Hills
GSK Investigational Site, Cleveland
GSK Investigational Site, Middleburg Heights
GSK Investigational Site, Cincinnati
GSK Investigational Site, Bingham Farms
GSK Investigational Site, Lenexa
GSK Investigational Site, Topeka
GSK Investigational Site, Omaha
GSK Investigational Site, Metairie
GSK Investigational Site, Little Rock
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Fort Worth
GSK Investigational Site, San Angelo
GSK Investigational Site, San Antonio
GSK Investigational Site, San Antonio
GSK Investigational Site, Austin
GSK Investigational Site, Denver
GSK Investigational Site, Colorado Springs
GSK Investigational Site, Murray
GSK Investigational Site, Phoenix
GSK Investigational Site, Phoenix
GSK Investigational Site, Tucson
GSK Investigational Site, Albuquerque
GSK Investigational Site, Las Vegas
GSK Investigational Site, Santa Monica
GSK Investigational Site, Warwick
XenoPort, Inc.
INDUSTRY